Huntington's Disease (HD) is one of 8 distinct human neurodegenerative disorders caused by expansion of an uninterrupted polyglutamine (polyQ) segment in the corresponding protein. The fact that the expanded polyQ segment is the only shared feature between these 8 proteins directly implicates the polyQ segment in neurotoxicity. In general, more than 40 consecutive glutamine residues in these proteins lead to the disease phenotype whereas fewer than 40 will not cause neurodegeneration. All 8 diseases are inherited in a genetically dominant manner and show an age of onset that is dependent on the length of the polyQ segment. In addition, each disease leads to a progressive deterioration towards death over 10-20 years. Despite the common features of these neurodegenerative disorders the precise molecular nature of polyQ toxicity is unknown. We are using the well characterized C. elegans nervous system to gain insight in the cellular mechanism of polyQ neurotoxicity. Previously we described a C. elegansmodel for polyQ-mediated cellular dysfunction utilizing small N-terminal fragments of the HD protein huntingtin (Htn) expressed in the ASH sensory neuron (PNAS 96, 179-184, 1999). These fragments contain polyQ stretches of 2, ", 95 or 150 residues. Expression of Htn-Q150, but not Htn-Q2, Htn-Q23 or Htn-Q95, caused age dependent ASH degeneration without ASH cell death in 8-day-old animals (as measured in dye-filling assays and immunohistochemical experiments). Despite the absence of cell death this degeneration was partly dependent on
ced-3 caspase function suggesting the involvement of the apoptotic cell death pathway in Htn-Q150 mediated neurodegeneration. To identify genes that normally function to counteract polyQ toxicity we performed an F2 EMS screen for mutations that lead to enhanced polyQ toxicity in the ASH neuron without compromising ASH survival/function in the absence of expanded polyQ segments. We anticipate that such mutations will define genes involved in turn-over and stability of Htn-Q150 or form part of the unknown cellular pathway(s) perturbed by expanded polyQ segments. We retained mutant strains that showed a >30% Htn-Q150 mediated ASH degeneration in 3 day old animals (as compared to <1% degeneration in the parental strain in 3 day old animals). After screening 30,000 mutagenized animals 7 independent mutations have been identified (
rt13,
rt58,
rt61,
rt62,
rt64,
rt65 and
rt67). In
rt13 mutant animals expressing Htn-Q150 about 80% of the ASH neurons were absent in 3 day old animals. In the absence of Htn-Q150 expression no ASH cell death was observed in these animals even at 8 days of age. In addition,
rt13 mutant animals are wild-type in two ASH mediated behavioral assays (nose-touch and osmotic avoidance). These results indicate that
rt13 does not generally impair ASH survival and function. Importantly, neither expression of Htn-Q2 nor a toxic control protein devoid of polyglutamines induced ASH cell death in 3 or 8 day old
rt13 animals. The Htn-Q150 mediated cell death in these animals is partly dependent on
ced-3 caspase function, again implicating the apoptotic cell death pathway in this process.
rt13 has been mapped to a small chromosomal interval that lacks obvious candidate genes. Phenotypic and complementation analysis of the 6 remaining mutations is under way. Identification of the molecular nature of
rt13 and related mutations might provide important insights in the molecular nature of polyQ pathogenesis and lead to novel therapeutic approaches for these neurodegenerative disorders.